Navigation Links
Malaria Vaccine Developer, Sanaria Inc., Receives 2009 Vaccine Industry Excellence Award for Best Early-Stage Vaccine Biotech
Date:6/2/2009

ROCKVILLE, Md., June 2 /PRNewswire/ -- The award was announced on April 21, 2009 at the World Vaccine Congress Washington conference. The Vaccine Industry Excellence awards recognize the accomplishments and contributions of companies and individuals working in the vaccine industry. Sanaria was named Best Early-Stage Vaccine Biotech from a group of nine companies shortlisted for the award. Other awardees included GlaxoSmithKline Biologicals for Best Vaccine R&D Pipeline and Merck for Best Prophylactic Vaccine.

"This award caps a remarkable period of rapid progress and success in translating Sanaria's whole-organism, sporozoite malaria vaccine candidate from development through cGMP manufacturing and the initiation of clinical trials. It recognizes the remarkable achievements and dedication of the entire Sanaria team and our collaborators," states Stephen L. Hoffman, Sanaria's founder and CEO.

Sanaria's candidate malaria vaccine is composed of live, attenuated parasites. This unique formulation, having satisfied rigorous FDA scrutiny for safety, sterility, purity, potency, and reproducibility of manufacturing, is now undergoing clinical testing in volunteers for safety and efficacy.

About Sanaria Inc. The company's primary mission is to develop and commercialize a malaria sporozoite vaccine against Plasmodium falciparum, the parasite responsible for more than 95 percent of malaria-associated severe illness and death worldwide, and the malaria parasite for which there is the most significant drug resistance. Sanaria's corporate headquarters, administrative, research, development, and manufacturing operations are located in Rockville, Maryland. The company's Web site is

http://www.sanaria.com.

Except for historical information, this news release contains certain forward-looking statements that involve known and unknown risk and uncertainties, which may cause actual results to differ materially from any future results, performance or achievements expressed or implied by the statements made. Such statements include expectations for the effectiveness of a vaccine and its usefulness. These forward-looking statements are further qualified by important factors that could cause actual results to differ materially from those in the forward-looking statements. These factors include, without limitation, the Company's ability to raise sufficient funds, the regulatory approval process, dependence on third-parties, clinical trials results, and the ability to commercialize the vaccine.

For further information contact: Media- Adam Richman 301.770.3222, Investors- Robert Thompson 240.403.2750


'/>"/>
SOURCE Sanaria Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Progress Against Malaria and Other Infectious Diseases Among Highlights at Annual Vaccine Conference
2. Phase 1 Trial of Whole-Parasite Malaria Vaccine to Begin
3. USAID Provides Malaria Assistance to Zimbabwe
4. Two New Studies in the New England Journal of Medicine Show Malaria Vaccine Candidate Advancing in Africa
5. Malaria Vaccine Developer Sanaria Inc. Receives the Technology Council of Marylands Emerging Company of the Year Award
6. SAIC Awarded Malaria Vaccine Production Support Contract Extension by the National Institute of Allergy and Infectious Diseases
7. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
8. Intercell AG Announces First Subject Enrolled in a Phase II Trial for the Further Development of Its Investigational Vaccine Enhancement Patch to Improve Pandemic Influenza Prevention in Collaboration With U.S. Department of Health and Human Services (HHS
9. Chuck Panozzo, Founder of Rock Band Styx, Joins GeoVax Labs, Inc. as an Advocate for Its HIV/AIDS Vaccine
10. Novel Vaccine Approach Offers Hope in Fight Against HIV
11. Novavax Completes Enrollment of Its Second Phase II Seasonal Influenza VLP Vaccine Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/5/2017)... NEWTOWN, Pa. , Sept. 5, 2017  Xyntek Inc. has announced another ... opened a new Midwest office to meet the growing demands of customer engagements ... Xyntek's new Midwest office is located at ... ... demands of customer engagements regionally. ...
(Date:9/5/2017)... 2017 Oramed Pharmaceuticals Inc. (NASDAQ: ... pharmaceutical company focused on the development of oral drug ... its meeting with the U.S. Food and Drug Administration ... At the meeting, ... for submission of ORMD-0801, would be a Biologics License ...
(Date:9/1/2017)... 2017  Bayer will present the latest research from across ... Oncology (ESMO) 2017 Congress, September 8-12 in Madrid, ... and clinical data on Bayer,s marketed portfolio and late-stage compounds ... "We value the opportunity ... research at ESMO," said Carsten Brunn , Head of ...
Breaking Medicine Technology:
(Date:9/20/2017)... ... 20, 2017 , ... Reflections Recovery Center, a men-only drug ... Joint Commission for chemical dependency and behavioral health services. , The Joint Commission ... that meet the commission’s rigorous standards. Accreditation by The Joint Commission is the ...
(Date:9/20/2017)... (PRWEB) , ... September 20, 2017 , ... Doctors on ... to their qualified network of medical professionals working on a personal injury lien basis. ... Spine Surgery Inc brings these esteemed doctors’ vast experience with orthopedic injuries to patients ...
(Date:9/20/2017)... Ohio (PRWEB) , ... September 20, 2017 , ... ... to customer service and innovation, the company recently unveiled a redesigned website. The ... further enrich the work of building owners, architects, contractors and other industry users ...
(Date:9/20/2017)... ... , ... Five consumer packaged goods (CPG) products were selected by the SupplySide ... Nopavera Plus was named to the short list in the Specialty Supplements category. ... presentations at SupplySide Central on Sept. 27 and 28 at Mandalay Bay Resort in ...
(Date:9/20/2017)... ... September 20, 2017 , ... “The Trials I Face to Receive God’s ... emotionally pens his aspirations and goals to better one’s life through God. “The Trials ... while searching in all the wrong places, found a love for writing. Green feels ...
Breaking Medicine News(10 mins):